Delivery Order SPE2DB20D3103-SPE2DB25FQ3R7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) valued at $1,711.94. This firm fixed-price delivery order is scheduled for completion by November 19, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive standing as a federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packaging) with a ceiling value of $1,227.78. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on November 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Envarsus XR 1 mg tablets (30-count units) valued at $1,035.60. This non-competitive delivery order, which will be completed by June 24, 2025, represents a firm fixed-price transaction issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) valued at $1,711.95. This competitively awarded, non-set-aside delivery order carries a firm fixed price and is scheduled for completion by October 6, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a ceiling value of $3,608.26. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 4, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, firm fixed-price delivery order is set to be completed by September 8, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery order issued under a larger contract vehicle rather than a standalone...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 4 mg tablets in a quantity of 100 units, with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for ultimate completion by October 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Envarsus XR 1 mg tablets in a 30-count package, with a ceiling value of $1,361.58. This non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by October 14, 2025. The delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units, with a ceiling value of $1,358.25. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and the order is scheduled for ultimate completion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Envarsus XR 1 mg tablets (100 count) with a ceiling value of $2,716.50. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by December 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ3R7Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for completion by October 8, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded through open procurement processes. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and running through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a diverse portfolio of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs and other federal health systems worldwide. The company's substantial IDC with DLA enables it to fulfill pharmaceutical needs across multiple therapeutic domains on an as-needed basis through individual delivery orders such as this one.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/17/25 |